SCHEMBL7202625

SCHEMBL7202625

NC(=O)N1CCC(S(=O)(=O)c2ccc(-c3ccccn3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.39
DPP4 P27487 2/20 0.39
DPP7 Q9UHL4 1/20 0.39
SLC6A7 Q99884 1/20 0.38
HTR2B P41595 1/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
KDM2B Q8NHM5 2/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
EPHX1 P07099 1/20 0.36
CYP2D6 P10635 1/20 0.36
EPHX2 P34913 1/20 0.36
NPY5R Q15761 1/20 0.36
SCD5 Q86SK9 2/20 0.36
TRPV4 Q9HBA0 1/20 0.36
GRIN2B Q13224 1/20 0.36
MMP1 P03956 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201014 0.88 SMN1; SMN2 (0.41) MMP1MMP9MMP13
SCHEMBL7205946 0.85 MMP1 (0.39) MMP1MMP9MMP13
SCHEMBL7292210 0.83 GHSR (0.46) CCR6DPP4DPP7F2F10
SCHEMBL7201292 0.83 PARP10 (0.44) MMP1MMP13
SCHEMBL7300738 0.82 MMP13 (0.48) MMP1MMP13
SCHEMBL7201540 0.82 ADAMTS4 (0.39) DPP4MMP1MMP13ADAM17
SCHEMBL7204066 0.82 ALDH1A1 (0.38) TRPV4MMP1MMP13
SCHEMBL7292292 0.82 AKR1C3 (0.45) DPP4DPP7F2F10KDM2B
SCHEMBL7205673 0.82 MMP1 (0.39) DPP4DPP7F10KDM2BMMP1
SCHEMBL7204213 0.82 MMP13 (0.52) DPP4DPP7SLC6A7KDM2BGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 CCR6 276/4885DPP4 2594/4885DPP7 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.